GoldBamboo.com - Knowledge is strong medicine
  

Data From Phase 1 Dose Escalation Study Of QUADRAMET(R) And Bortezomib In Patients With Relapsed Multiple Myeloma - News


  Not Signed In - Sign In / Register


Get Your Free Credit Report Right Now!

Zip Code:



General Topics A-Z

Data From Phase 1 Dose Escalation Study Of QUADRAMET(R) And Bortezomib In Patients With Relapsed Multiple Myeloma

Tue, 12 Dec 2006 08:00 AM EST

... Cytogen Corporation (Nasdaq: CYTO) reported the presentation of updated data from an ongoing Phase 1 dose escalation study evaluating QUADRAMET(R) (samarium Sm-153 lexidronam injection) in combination with bortezomib (Velcade(R), Millennium Pharmaceuticals, Inc.) in patients with relapsed multiple myeloma. [click link for full article] ...

Related Topics

Take control over your directory listings...INSTANTLY

Every day, thousands of users find businesses like yours in the GoldBamboo directory.

Limited Time Offer!!!

For only $30 a year, a savings of 70% off our standard rate:

  • Edit your listing (whenever you want!)
  • Link to your website
  • Choose which categories you are listed in
  • Describe your services

The process will take only a few minutes and consists of 3 easy steps:

1. Register     >     2. Edit Listings     >     3. Publish

Your Company
your street
yourtown, YS 12345
888-888-8888



No Thanks

GoldBambooTM

Your Integrative Health and Wellness Resource

November 21, 2009


Page Updated: January 17, 2009
============== Advertisement ==============
Disclaimer: All material displayed on the GoldBamboo.com website is provided for educational purposes only. Consult a physician regarding the applicability of any information found on GoldBamboo.com to your symptoms or medical condition.

Home | About Us | Link To Us | Feedback | Disclaimer | Privacy Policy | Terms of Use | Health Forums

Copyright © 2004-2009 - Anaconda Partners LLC - All rights reserved.

HONcode accreditation seal.

We comply with the HONcode standard for health trust worthy information:
verify here.